Cosmo H1 FY26 operating loss widens to EUR 6.61 million; revenue falls to EUR 50.24 million

• Cosmo posted H1 2026 revenue of EUR 50.2 million, including recurring revenue of EUR 49.6 million, up 18% year on year.
• Operating loss widened to EUR 6.6 million; loss attributable to shareholders widened to EUR 4.75 million, or EUR 0.279 per share.
• EBITDA swung to EUR 0.01 million loss from a profit, while cash, equivalents and investments rose to EUR 205.1 million at June 30.
• Winlevi revenue climbed 38% to EUR 10.2 million; Lialda/Mezavant/Mesavancol revenue rose to EUR 19 million.
• GI Genius revenue increased 5% to EUR 9.2 million; management reiterated expectations for double-digit growth in H2 2026 and full-year 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.